The single most-pursued target in our radar, TNF-alpha, shows up attached to twenty-six different diseases — not two or three, but twenty-six, from inflammation to seizures to metabolic disease. That's not scattershot. It's the signature of a validated mechanism multiplying.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
A proven mechanism radiates
Once a mechanism is shown to work in one condition, the science fans outward — researchers and companies test it against every disease where the same biology might be at play. Each new indication is a new reason to make the drug, and a new slice of demand for the same chemistry.
The pattern is easy to miss in a single approval and obvious once you step back and count. A target that touches one disease is a hypothesis; a handful is a program; two dozen is a settled bet that an entire field has decided to press in every direction at once. That is what a validated mechanism looks like from a distance — not a single drug, but a widening cone of demand aimed at the same chemistry.
The textbook case is anti-TNF itself. Adalimumab — sold as Humira — became the best-selling drug in history, with more than $200 billion in sales, not by treating one disease but by being approved across roughly ten: rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, and more. [1] Same molecule, same mechanism, expanded disease by disease. Every expansion multiplied the demand.
Why validation is the hardest step — and how it transfers
Drug development is a sequence of gates: pick a target, find a molecule that hits it, show the molecule is safe, and then show that hitting the target actually changes the disease in real patients. The last gate is the one that breaks most programs. A molecule can be beautifully designed, bind exactly where it should, and behave perfectly in the lab — and still fail, because the biology it was aimed at turned out not to matter as much as everyone believed. This is why the industry's most expensive failures are so often failures of efficacy, not chemistry. The target simply wasn't as central to the disease as the early evidence suggested.
Target validation is hard precisely because it can't be shortcut. Cell lines, animal models, and biomarkers are all approximations of human disease, and each one can point the wrong way. The definitive answer usually arrives late and expensively, in patients. That's what makes a cleared target so valuable: once a mechanism is proven to move a disease in humans, the single largest uncertainty in the whole enterprise collapses. You now know the biology is real, the target is druggable, and modulating it produces meaningful benefit.
And here is the multiplier. That answer doesn't stay locked to one disease. Wherever the same signaling drives a different condition, much of the hard question is already settled — the mechanism is proven, so the new program inherits the validation instead of re-earning it. TNF blockade, having worked in rheumatoid arthritis, became a rational bet in psoriasis, in inflammatory bowel disease, and across a dozen conditions where the same inflammatory signal runs hot. Each of those was a new program riding on borrowed certainty, and each was a new stream of demand for the identical molecule.
One asset, many labels: the lifecycle strategy
The industry has a deliberate playbook for this, usually called lifecycle management, and its object is the franchise molecule. Rather than treat a first approval as the finish line, companies treat it as the first of many. The revenue from indication one funds the trials for indication two; each new label opens a fresh market without requiring a new molecule. New formulations, new dosing, and new patient populations extend the same asset further still.
The economics make the strategy irresistible. The enormous cost of discovering and de-risking a molecule is largely sunk once it reaches first approval. Every additional indication after that is mostly the price of a clinical trial, not of inventing new chemistry. So the marginal return on each expansion is high, and the incentive is to keep expanding as long as the biology allows. Adalimumab is the masterpiece of the form: one antibody, roughly ten diseases, more than two hundred billion dollars, all built on a single validated mechanism.
For anyone reading demand rather than a stock price, the takeaway is cleaner still. A franchise molecule doesn't produce one burst of orders — it produces a decade of them, layered on as each label lands. The chemistry is identical throughout; what changes is only how many reasons the world has found to keep making it.
The biosimilar cliff — where the demand goes
Exclusivity does not last forever. When the patents and protections around a franchise molecule lapse, biosimilars and generics enter, and prices fall hard — for adalimumab, with list prices dropping to as much as roughly 85% below the originator's. The intuitive conclusion is that demand collapses along with the price. The intuition is wrong.
What actually happens is that demand for the molecule holds — often it even grows, because a far cheaper drug reaches patients who were previously priced out. The chemistry keeps being ordered. What moves is not the volume but the beneficiary. Demand migrates from the originator to whoever can manufacture the same molecule most efficiently, most reliably, and at the quality regulators require. A validated target, in other words, keeps its chemistry in demand long after the first approval; the exclusivity cliff changes who captures that demand, not whether it exists.
This is the quiet half of the story a sales-ranking chart never shows. When a headline says a blockbuster is "falling off a cliff," it describes the originator's revenue, not the molecule's relevance. The molecule is as needed as ever; it has simply changed hands from an inventor to a set of manufacturers competing to make it best.
Who feels this: originators, makers, and scouts
The originator lives the first act. It captures the validation windfall, runs the label-expansion sequence for as long as the biology cooperates, and defends its position with next-generation molecules, improved formulations, and combination strategies aimed at extending the franchise before the cliff arrives. Everything hinges on turning one proven mechanism into as many indications as the science will support.
The second act belongs to the makers — biosimilar and generic developers and the contract manufacturers who produce for them. They enter after exclusivity ends and compete on a different axis entirely: manufacturing efficiency, product quality, cost, and supply reliability. This is where the migrated demand lands. A validated molecule doesn't reward the cleverest marketing after the cliff; it rewards the most capable factory. For a CDMO, a mechanism that has fanned out across dozens of indications is a signal that the underlying chemistry will be ordered for years, by many customers, well past any single patent.
The third group watches all of it: the business-development and licensing scouts hunting for validated-but-unclaimed opportunities. Their question is where a proven mechanism is radiating faster than the field has exploited — an indication adjacent to a settled target that no one has yet pursued, or a validated target where a better-executed molecule could take share. What they want most is to see it early: which mechanisms are fanning out, and toward what, before the labels catch up and the opportunity is obvious to everyone.
The catch: a validated target is not a validated molecule
The multiplier is real but not automatic, and two caveats keep it honest. The first: a validated mechanism does not guarantee every indication will work. Biology is context-dependent — a pathway that dominates one disease can be secondary in another, and the same intervention that calms one inflammatory condition has, in other settings, done nothing or even made patients worse. Radiating is a strong prior, not a promise. The cone of demand widens because the base rate of success improves sharply once a mechanism is proven, not because failure becomes impossible.
The second caveat is the subtler and more important one: a validated target is not the same as a validated molecule. Proving that a mechanism matters tells you the biology is worth hitting. It does not tell you that any particular molecule aimed at it will be safe, effective, differentiated, or even manufacturable. Two molecules against the same settled target can produce very different outcomes in the clinic and in the factory. The demand a validated target creates is demand for a chemistry class realized through whichever molecule executes best.
That distinction is why the biosimilar migration matters so much. Once the target is settled, the molecule becomes the whole contest — who makes it, how well, at what cost. Validation decides that the chemistry will be in demand; execution decides who gets to satisfy it.
Why a validated target is worth watching even when it's "old"
Validation is a demand multiplier. It turns one program into ten, one market into many, and it keeps the underlying chemistry in demand for years after the first approval. So when the radar shows a single target fanning out across dozens of indications, it isn't noise — it's the early shape of a mechanism about to be tried everywhere. Read the fan-out, and you can watch demand compound before the labels catch up. That is the science-to-demand chain in its purest form: one validated idea, radiating into years of orders.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.